The p53 family reaches the final frontier: the variegated regulation of the dark matter of the genome by the p53 family in cancer

References

• International Human Genome Sequencing C. Finishing the euchromatic sequence of the human genome. Nature. 2004;431:931–945.
   PubMed Web of Science ®Google Scholar
• Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860–921.
   PubMed Web of Science ®Google Scholar
• Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science. 2001;291:1304–1351.
   PubMed Web of Science ®Google Scholar
• Hangauer MJ, Vaughn IW, McManus MT. Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs. PLoS Genet. 2013;9:e1003569.
   PubMed Web of Science ®Google Scholar
• Kapranov P, St Laurent G, Raz T, et al. The majority of total nuclear-encoded non-ribosomal RNA in a human cell is ‘dark matter’ un-annotated RNA. BMC Biol. 2010;8:149.
   PubMed Web of Science ®Google Scholar
• Jankowsky E, Harris ME. Specificity and nonspecificity in RNA-protein interactions. Nat Rev Mol Cell Biol. 2015;16:533–544.
   PubMed Web of Science ®Google Scholar
• Weick EM, Miska EA. piRNAs: from biogenesis to function. Development. 2014;141:3458–3471.
   PubMed Web of Science ®Google Scholar
• Michlewski G, Caceres JF. Post-transcriptional control of miRNA biogenesis. RNA. 2019;25:1–16.
   PubMed Web of Science ®Google Scholar
• Yao RW, Wang Y, Chen LL. Cellular functions of long noncoding RNAs. Nat Cell Biol. 2019;21:542–551.
   PubMed Web of Science ®Google Scholar
• Patop IL, Wust S, Kadener S. Past, present, and future of circRNAs. Embo J. 2019;38(16):e100836.
   PubMed Web of Science ®Google Scholar
• Chatterjee M, Sengupta S. Emerging roles of long non-coding RNAs in cancer. J Biosci. 2019;44:22.
   PubMed Web of Science ®Google Scholar
• Dragomir M, Calin GA. Circular RNAs in cancer - lessons learned from microRNAs. Front Oncol. 2018;8:179.
   PubMed Web of Science ®Google Scholar
• Hata A, Kashima R. Dysregulation of microRNA biogenesis machinery in cancer. Crit Rev Biochem Mol Biol. 2016;51:121–134.
   PubMed Web of Science ®Google Scholar
• Huang SQ, Sun B, Xiong ZP, et al. The dysregulation of tRNAs and tRNA derivatives in cancer. J Exp Clin Cancer Res. 2018;37:101.
   PubMed Web of Science ®Google Scholar
• Nguyen le XT, Raval A, Garcia JS, et al. Regulation of ribosomal gene expression in cancer. J Cell Physiol. 2015;230:1181–1188.
   PubMed Web of Science ®Google Scholar
• Goeman F, Strano S, Blandino G. MicroRNAs as key effectors in the p53 network. Int Rev Cell Mol Biol. 2017;333:51–90.
   PubMed Web of Science ®Google Scholar
• Kaiser AM, Attardi LD. Deconstructing networks of p53-mediated tumor suppression in vivo. Cell Death Differ. 2018;25:93–103.
   PubMed Web of Science ®Google Scholar
• Lin T, Hou PF, Meng S, et al. Emerging roles of p53 related lncRNAs in cancer progression: a systematic review. Int J Biol Sci. 2019;15:1287–1298.
   PubMed Web of Science ®Google Scholar
• Napoli M, Flores ER. The family that eats together stays together: new p53 family transcriptional targets in autophagy. Genes Dev. 2013;27:971–974.
   PubMed Web of Science ®Google Scholar
• Napoli M, Flores ER. The p53 family orchestrates the regulation of metabolism: physiological regulation and implications for cancer therapy. Br J Cancer. 2017;116:149–155.
   PubMed Web of Science ®Google Scholar
• Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333–339.
   PubMed Web of Science ®Google Scholar
• Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215–221.
   PubMed Web of Science ®Google Scholar
• Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994;4:1–7.
   PubMed Web of Science ®Google Scholar
• Lang GA, Iwakuma T, Suh YA, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004;119:861–872.
   PubMed Web of Science ®Google Scholar
• Olive KP, Tuveson DA, Ruhe ZC, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004;119:847–860.
   PubMed Web of Science ®Google Scholar
• Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358:15–16.
   PubMed Web of Science ®Google Scholar
• Flores ER, Sengupta S, Miller JB, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell. 2005;7:363–373.
   PubMed Web of Science ®Google Scholar
• Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 2002;416:560–564.
   PubMed Web of Science ®Google Scholar
• Pflaum J, Schlosser S, Muller M. p53 family and cellular stress responses in cancer. Front Oncol. 2014;4:285.
   PubMedGoogle Scholar
• Qian Y, Chen X. Senescence regulation by the p53 protein family. Methods Mol Biol. 2013;965:37–61.
   PubMedGoogle Scholar
• Lin YL, Sengupta S, Gurdziel K, et al. p63 and p73 transcriptionally regulate genes involved in DNA repair. PLoS Genet. 2009;5:e1000680.
   PubMed Web of Science ®Google Scholar
• Prokhorova EA, Zamaraev AV, Kopeina GS, et al. Role of the nucleus in apoptosis: signaling and execution. Cell Mol Life Sci. 2015;72:4593–4612.
   PubMed Web of Science ®Google Scholar
• Mills AA, Zheng B, Wang XJ, et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature. 1999;398:708–713.
   PubMed Web of Science ®Google Scholar
• Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999;398:714–718.
   PubMed Web of Science ®Google Scholar
• Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature. 2000;404:99–103.
   PubMed Web of Science ®Google Scholar
• Chen Y, Peng Y, Fan S, et al. A double dealing tale of p63: an oncogene or a tumor suppressor. Cell Mol Life Sci. 2018;75:965–973.
   PubMed Web of Science ®Google Scholar
• Joruiz SM, Bourdon JC. p53 isoforms: key regulators of the cell fate decision. Cold Spring Harb Perspect Med. 2016;6:a026039.
   PubMed Web of Science ®Google Scholar
• Vikhreva P, Melino G, Amelio I. p73 alternative splicing: exploring a biological role for the C-terminal isoforms. J Mol Biol. 2018;430:1829–1838.
   PubMed Web of Science ®Google Scholar
• Candi E, Dinsdale D, Rufini A, et al. TAp63 and DeltaNp63 in cancer and epidermal development. Cell Cycle. 2007;6:274–285.
   PubMed Web of Science ®Google Scholar
• Venkatanarayan A, Raulji P, Norton W, et al. IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo. Nature. 2015;517:626–630.
   PubMed Web of Science ®Google Scholar
• Napoli M, Venkatanarayan A, Raulji P, et al. DeltaNp63/DGCR8-dependent micrornas mediate therapeutic efficacy of HDAC inhibitors in cancer. Cancer Cell. 2016;29:874–888.
   PubMed Web of Science ®Google Scholar
• Orzol P, Holcakova J, Nekulova M, et al. The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site. Histol Histopathol. 2015;30:503–521.
   PubMed Web of Science ®Google Scholar
• Su X, Chakravarti D, Cho MS, et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature. 2010;467:986–990.
   PubMed Web of Science ®Google Scholar
• Tomasini R, Tsuchihara K, Wilhelm M, et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev. 2008;22:2677–2691.
   PubMed Web of Science ®Google Scholar
• Su X, Paris M, Gi YJ, et al. TAp63 prevents premature aging by promoting adult stem cell maintenance. Cell Stem Cell. 2009;5:64–75.
   PubMed Web of Science ®Google Scholar
• Su X, Napoli M, Abbas HA, et al. TAp63 suppresses mammary tumorigenesis through regulation of the Hippo pathway. Oncogene. 2017;36:2377–2393.
   PubMed Web of Science ®Google Scholar
• Su X, Gi YJ, Chakravarti D, et al. TAp63 is a master transcriptional regulator of lipid and glucose metabolism. Cell Metab. 2012;16:511–525.
   PubMed Web of Science ®Google Scholar
• Napoli M, Flores ER. Unifying the p73 knockout phenotypes: tAp73 orchestrates multiciliogenesis. Genes Dev. 2016;30:1253–1254.
   PubMed Web of Science ®Google Scholar
• Nemajerova A, Kramer D, Siller SS, et al. TAp73 is a central transcriptional regulator of airway multiciliogenesis. Genes Dev. 2016;30:1300–1312.
   PubMed Web of Science ®Google Scholar
• Chakravarti D, Su X, Cho MS, et al. Induced multipotency in adult keratinocytes through down-regulation of DeltaNp63 or DGCR8. Proc Natl Acad Sci U S A. 2014;111:E572–81.
   PubMed Web of Science ®Google Scholar
• Romano RA, Smalley K, Magraw C, et al. DeltaNp63 knockout mice reveal its indispensable role as a master regulator of epithelial development and differentiation. Development. 2012;139:772–782.
   PubMed Web of Science ®Google Scholar
• Restelli M, Lopardo T, Lo Iacono N, et al. DLX5, FGF8 and the Pin1 isomerase control DeltaNp63alpha protein stability during limb development: a regulatory loop at the basis of the SHFM and EEC congenital malformations. Hum Mol Genet. 2014;23:3830–3842.
   PubMed Web of Science ®Google Scholar
• Tissir F, Ravni A, Achouri Y, et al. DeltaNp73 regulates neuronal survival in vivo. Proc Natl Acad Sci U S A. 2009;106:16871–16876.
   PubMed Web of Science ®Google Scholar
• Wilhelm MT, Rufini A, Wetzel MK, et al. Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes Dev. 2010;24:549–560.
   PubMed Web of Science ®Google Scholar
• Bohnsack KE, Bohnsack MT. Uncovering the assembly pathway of human ribosomes and its emerging links to disease. Embo J. 2019;38:e100278.
   PubMed Web of Science ®Google Scholar
• Boisvert FM, van Koningsbruggen S, Navascues J, et al. The multifunctional nucleolus. Nat Rev Mol Cell Biol. 2007;8:574–585.
   PubMed Web of Science ®Google Scholar
• Nerurkar P, Altvater M, Gerhardy S, et al. Eukaryotic ribosome assembly and nuclear export. Int Rev Cell Mol Biol. 2015;319:107–140.
   PubMed Web of Science ®Google Scholar
• Mayer C, Grummt I. Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases. Oncogene. 2006;25:6384–6391.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhao LN, Li KZ, et al. Overexpression of ribosomal protein L15 is associated with cell proliferation in gastric cancer. BMC Cancer. 2006;6:91.
   PubMed Web of Science ®Google Scholar
• Wang M, Hu Y, Stearns ME. RPS2: a novel therapeutic target in prostate cancer. J Exp Clin Cancer Res. 2009;28:6.
   PubMed Web of Science ®Google Scholar
• Derenzini E, Rossi A, Trere D. Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why. J Hematol Oncol. 2018;11:75.
   PubMed Web of Science ®Google Scholar
• Yang K, Yang J, Yi J. Nucleolar Stress: hallmarks, sensing mechanism and diseases. Cell Stress. 2018;2:125–140.
   PubMedGoogle Scholar
• Deisenroth C, Franklin DA, Zhang Y. The evolution of the ribosomal protein-MDM2-p53 pathway. Cold Spring Harb Perspect Med. 2016;6:a026138.
   PubMed Web of Science ®Google Scholar
• Dai MS, Lu H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem. 2004;279:44475–44482.
   PubMed Web of Science ®Google Scholar
• Lohrum MA, Ludwig RL, Kubbutat MH, et al. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell. 2003;3:577–587.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wolf GW, Bhat K, et al. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol. 2003;23:8902–8912.
   PubMed Web of Science ®Google Scholar
• Bernardi R, Scaglioni PP, Bergmann S, et al. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol. 2004;6:665–672.
   PubMed Web of Science ®Google Scholar
• Takagi M, Absalon MJ, McLure KG, et al. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell. 2005;123:49–63.
   PubMed Web of Science ®Google Scholar
• Ofir-Rosenfeld Y, Boggs K, Michael D, et al. Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol Cell. 2008;32:180–189.
   PubMed Web of Science ®Google Scholar
• White RJ. RNA polymerases I and III, non-coding RNAs and cancer. Trends Genet. 2008;24:622–629.
   PubMed Web of Science ®Google Scholar
• Oskarsson T, Trumpp A. The Myc trilogy: lord of RNA polymerases. Nat Cell Biol. 2005;7:215–217.
   PubMed Web of Science ®Google Scholar
• Golomb L, Bublik DR, Wilder S, et al. Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. Mol Cell. 2012;45:222–232.
   PubMed Web of Science ®Google Scholar
• Bursac S, Brdovcak MC, Donati G, et al. Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis. Biochim Biophys Acta. 2014;1842:817–830.
   PubMed Web of Science ®Google Scholar
• Panic L, Tamarut S, Sticker-Jantscheff M, et al. Ribosomal protein S6 gene haploinsufficiency is associated with activation of a p53-dependent checkpoint during gastrulation. Mol Cell Biol. 2006;26:8880–8891.
   PubMed Web of Science ®Google Scholar
• Barkic M, Crnomarkovic S, Grabusic K, et al. The p53 tumor suppressor causes congenital malformations in Rpl24-deficient mice and promotes their survival. Mol Cell Biol. 2009;29:2489–2504.
   PubMed Web of Science ®Google Scholar
• Anderson SJ, Lauritsen JP, Hartman MG, et al. Ablation of ribosomal protein L22 selectively impairs alphabeta T cell development by activation of a p53-dependent checkpoint. Immunity. 2007;26:759–772.
   PubMed Web of Science ®Google Scholar
• Terzian T, Dumble M, Arbab F, et al. Rpl27a mutation in the sooty foot ataxia mouse phenocopies high p53 mouse models. J Pathol. 2011;224:540–552.
   PubMed Web of Science ®Google Scholar
• Marini A, Rotblat B, Sbarrato T, et al. TAp73 contributes to the oxidative stress response by regulating protein synthesis. Proc Natl Acad Sci U S A. 2018;115:6219–6224.
   PubMed Web of Science ®Google Scholar
• Rotblat B, Agostini M, Niklison-Chirou MV, et al. Sustained protein synthesis and reduced eEF2K levels in TAp73(-\-) mice brain: a possible compensatory mechanism. Cell Cycle. 2018;17:2637–2643.
   PubMed Web of Science ®Google Scholar
• Boldrup L, Coates PJ, Laurell G, et al. p63 Transcriptionally regulates BNC1, a Pol I and Pol II transcription factor that regulates ribosomal biogenesis and epithelial differentiation. Eur J Cancer. 2012;48:1401–1406.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang S, Schultz RM, et al. Search for basonuclin target genes. Biochem Biophys Res Commun. 2006;348:1261–1271.
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang J, Tseng H. Basonuclin regulates a subset of ribosomal RNA genes in HaCaT cells. PLoS One. 2007;2:e902.
   PubMed Web of Science ®Google Scholar
• Cui C, Elsam T, Tian Q, et al. Gli proteins up-regulate the expression of basonuclin in basal cell carcinoma. Cancer Res. 2004;64:5651–5658.
   PubMed Web of Science ®Google Scholar
• Brighenti E, Trere D, Derenzini M. Targeted cancer therapy with ribosome biogenesis inhibitors: a real possibility? Oncotarget. 2015;6:38617–38627.
   PubMedGoogle Scholar
• Drygin D, Lin A, Bliesath J, et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res. 2011;71:1418–1430.
   PubMed Web of Science ®Google Scholar
• Bywater MJ, Poortinga G, Sanij E, et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell. 2012;22:51–65.
   PubMed Web of Science ®Google Scholar
• Chen YT, Chen JJ, Wang HT. Targeting RNA polymerase I with hernandonine inhibits ribosomal RNA synthesis and tumor cell growth. Mol Cancer Res. 2019;17:2294–2305.
   Web of Science ®Google Scholar
• Hoagland MB, Stephenson ML, Scott JF, et al. A soluble ribonucleic acid intermediate in protein synthesis. J Biol Chem. 1958;231:241–257.
   PubMed Web of Science ®Google Scholar
• Goodarzi H, HCB N, Zhang S, et al. Modulated expression of specific tRNAs drives gene expression and cancer progression. Cell. 2016;165:1416–1427.
   PubMed Web of Science ®Google Scholar
• Santos M, Fidalgo A, Varanda AS, et al. tRNA deregulation and its consequences in cancer. Trends Mol Med. 2019;25(10):853–865.
   Web of Science ®Google Scholar
• Dittmar KA, Goodenbour JM, Pan T. Tissue-specific differences in human transfer RNA expression. PLoS Genet. 2006;2:e221.
   PubMed Web of Science ®Google Scholar
• Ishimura R, Nagy G, Dotu I, et al. RNA function. Ribosome stalling induced by mutation of a CNS-specific tRNA causes neurodegeneration. Science. 2014;345:455–459.
   PubMed Web of Science ®Google Scholar
• Sriskanthadevan-Pirahas S, Deshpande R, Lee B, et al. Ras/ERK-signalling promotes tRNA synthesis and growth via the RNA polymerase III repressor Maf1 in Drosophila. PLoS Genet. 2018;14:e1007202.
   PubMed Web of Science ®Google Scholar
• Kantidakis T, Ramsbottom BA, Birch JL, et al. mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1. Proc Natl Acad Sci U S A. 2010;107:11823–11828.
   PubMed Web of Science ®Google Scholar
• Khattar E, Kumar P, Liu CY, et al. Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expression. J Clin Invest. 2016;126:4045–4060.
   PubMed Web of Science ®Google Scholar
• Wang B, Li D, Kovalchuk I, et al. miR-34a directly targets tRNAi(Met) precursors and affects cellular proliferation, cell cycle, and apoptosis. Proc Natl Acad Sci U S A. 2018;115:7392–7397.
   PubMed Web of Science ®Google Scholar
• Birch J, Clarke CJ, Campbell AD, et al. The initiator methionine tRNA drives cell migration and invasion leading to increased metastatic potential in melanoma. Biol Open. 2016;5:1371–1379.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Ye Y, Gong J, et al. Global analysis of tRNA and translation factor expression reveals a dynamic landscape of translational regulation in human cancers. Commun Biol. 2018;1:234.
   PubMed Web of Science ®Google Scholar
• Kuang M, Zheng D, Tao X, et al. tRNA-based prognostic score in predicting survival outcomes of lung adenocarcinomas. Int J Cancer. 2019;145:1982–1990.
   PubMed Web of Science ®Google Scholar
• Yang JR, Chen X, Zhang J. Codon-by-codon modulation of translational speed and accuracy via mRNA folding. PLoS Biol. 2014;12:e1001910.
   PubMed Web of Science ®Google Scholar
• Santos M, Pereira PM, Varanda AS, et al. Codon misreading tRNAs promote tumor growth in mice. RNA Biol. 2018;15:773–786.
   PubMed Web of Science ®Google Scholar
• Ribas de Pouplana L, Santos MA, Zhu JH, et al. Protein mistranslation: friend or foe? Trends Biochem Sci. 2014;39:355–362.
   PubMed Web of Science ®Google Scholar
• Hetz C, Papa FR. The unfolded protein response and cell fate control. Mol Cell. 2018;69:169–181.
   PubMed Web of Science ®Google Scholar
• Stavridi ES, Halazonetis TD. p53 and stress in the ER. Genes Dev. 2004;18:241–244.
   PubMedGoogle Scholar
• Pyati UJ, Gjini E, Carbonneau S, et al. p63 mediates an apoptotic response to pharmacological and disease-related ER stress in the developing epidermis. Dev Cell. 2011;21:492–505.
   PubMed Web of Science ®Google Scholar
• Ramadan S, Terrinoni A, Catani MV, et al. p73 induces apoptosis by different mechanisms. Biochem Biophys Res Commun. 2005;331:713–717.
   PubMed Web of Science ®Google Scholar
• Hetz C, Axten JM, Patterson JB. Pharmacological targeting of the unfolded protein response for disease intervention. Nat Chem Biol. 2019;15:764–775.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–233.
   PubMed Web of Science ®Google Scholar
• Ruby JG, Jan CH, Bartel DP. Intronic microRNA precursors that bypass drosha processing. Nature. 2007;448:83–86.
   PubMed Web of Science ®Google Scholar
• Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. Embo J. 2004;23:4051–4060.
   PubMed Web of Science ®Google Scholar
• Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA. 2004;10:1957–1966.
   PubMed Web of Science ®Google Scholar
• Han J, Lee Y, Yeom KH, et al. Molecular basis for the recognition of primary microRNAs by the drosha-DGCR8 complex. Cell. 2006;125:887–901.
   PubMed Web of Science ®Google Scholar
• Lee Y, Ahn C, Han J, et al. The nuclear RNase III drosha initiates microRNA processing. Nature. 2003;425:415–419.
   PubMed Web of Science ®Google Scholar
• Yi R, Qin Y, Macara IG, et al. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 2003;17:3011–3016.
   PubMed Web of Science ®Google Scholar
• Bernstein E, Caudy AA, Hammond SM, et al. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 2001;409:363–366.
   PubMed Web of Science ®Google Scholar
• Gregory RI, Chendrimada TP, Cooch N, et al. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell. 2005;123:631–640.
   PubMed Web of Science ®Google Scholar
• Suzuki HI, Yamagata K, Sugimoto K, et al. Modulation of microRNA processing by p53. Nature. 2009;460:529–533.
   PubMed Web of Science ®Google Scholar
• Krell J, Stebbing J, Frampton AE, et al. The role of TP53 in miRNA loading onto AGO2 and in remodelling the miRNA-mRNA interaction network. Lancet. 2015;385(Suppl 1):S15.
   PubMedGoogle Scholar
• Kumar MS, Pester RE, Chen CY, et al. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev. 2009;23:2700–2704.
   PubMed Web of Science ®Google Scholar
• Abbas HA, Bui NHB, Rajapakshe K, et al. Distinct TP63 isoform-driven transcriptional signatures predict tumor progression and clinical outcomes. Cancer Res. 2018;78:451–462.
   PubMed Web of Science ®Google Scholar
• He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007;447:1130–1134.
   PubMed Web of Science ®Google Scholar
• Brosh R, Shalgi R, Liran A, et al. p53-repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol. 2008;4:229.
   PubMed Web of Science ®Google Scholar
• Rivetti Di Val Cervo P, Lena AM, Nicoloso, et al. p63-microRNA feedback in keratinocyte senescence. Proc Natl Acad Sci U S A. 2012;109:1133–1138.
   PubMed Web of Science ®Google Scholar
• Huang Y, Kesselman D, Kizub D, et al. Phospho-DeltaNp63alpha/microRNA feedback regulation in squamous carcinoma cells upon cisplatin exposure. Cell Cycle. 2013;12:684–697.
   PubMed Web of Science ®Google Scholar
• Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10:593–601.
   PubMed Web of Science ®Google Scholar
• Lu Y, Cao J, Napoli M, et al. miR-205 regulates basal cell identity and stem cell regenerative potential during mammary reconstitution. Stem Cells. 2018;36:1875–1889.
   PubMed Web of Science ®Google Scholar
• Tran MN, Choi W, Wszolek MF, et al. The p63 protein isoform DeltaNp63alpha inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. J Biol Chem. 2013;288:3275–3288.
   PubMed Web of Science ®Google Scholar
• Tucci P, Agostini M, Grespi F, et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A. 2012;109:15312–15317.
   PubMed Web of Science ®Google Scholar
• Ory B, Ramsey MR, Wilson C, et al. A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma. J Clin Invest. 2011;121:809–820.
   PubMed Web of Science ®Google Scholar
• Le MT, Teh C, Shyh-Chang N, et al. MicroRNA-125b is a novel negative regulator of p53. Genes Dev. 2009;23:862–876.
   PubMed Web of Science ®Google Scholar
• Lena AM, Shalom-Feuerstein R, Rivetti Di Val Cervo P, et al. miR-203 represses ‘stemness’ by repressing DeltaNp63. Cell Death Differ. 2008;15:1187–1195.
   PubMed Web of Science ®Google Scholar
• Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155–159.
   PubMed Web of Science ®Google Scholar
• Ponting CP, Belgard TG. Transcribed dark matter: meaning or myth? Hum Mol Genet. 2010;19:R162–8.
   PubMed Web of Science ®Google Scholar
• Wang X, Arai S, Song X, et al. Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature. 2008;454:126–130.
   PubMed Web of Science ®Google Scholar
• Kornienko AE, Guenzl PM, Barlow DP, et al. Gene regulation by the act of long non-coding RNA transcription. BMC Biol. 2013;11:59.
   PubMed Web of Science ®Google Scholar
• Faghihi MA, Modarresi F, Khalil AM, et al. Expression of a noncoding RNA is elevated in Alzheimer’s disease and drives rapid feed-forward regulation of beta-secretase. Nat Med. 2008;14:723–730.
   PubMed Web of Science ®Google Scholar
• Cesana M, Cacchiarelli D, Legnini I, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell. 2011;147:358–369.
   PubMed Web of Science ®Google Scholar
• Halic M, Becker T, Pool MR, et al. Structure of the signal recognition particle interacting with the elongation-arrested ribosome. Nature. 2004;427:808–814.
   PubMed Web of Science ®Google Scholar
• Zappulla DC, Cech TR. Yeast telomerase RNA: a flexible scaffold for protein subunits. Proc Natl Acad Sci U S A. 2004;101:10024–10029.
   PubMed Web of Science ®Google Scholar
• Mao YS, Sunwoo H, Zhang B, et al. Direct visualization of the co-transcriptional assembly of a nuclear body by noncoding RNAs. Nat Cell Biol. 2011;13:95–101.
   PubMed Web of Science ®Google Scholar
• Yu W, Gius D, Onyango P, et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature. 2008;451:202–206.
   PubMed Web of Science ®Google Scholar
• Meseure D, Vacher S, Alsibai KD, et al. Expression of ANRIL-polycomb complexes-CDKN2A/B/ARF genes in breast tumors: identification of a two-gene (EZH2/CBX7) signature with independent prognostic value. Mol Cancer Res. 2016;14:623–633.
   PubMed Web of Science ®Google Scholar
• Li J, Poi MJ, Tsai MD. Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer. Biochemistry. 2011;50:5566–5582.
   PubMed Web of Science ®Google Scholar
• Lin L, Gu ZT, Chen WH, et al. Increased expression of the long non-coding RNA ANRIL promotes lung cancer cell metastasis and correlates with poor prognosis. Diagn Pathol. 2015;10:14.
   PubMed Web of Science ®Google Scholar
• Qiu JJ, Lin YY, Ding JX, et al. Long non-coding RNA ANRIL predicts poor prognosis and promotes invasion/metastasis in serous ovarian cancer. Int J Oncol. 2015;46:2497–2505.
   PubMed Web of Science ®Google Scholar
• Tseng YY, Moriarity BS, Gong W, et al. PVT1 dependence in cancer with MYC copy-number increase. Nature. 2014;512:82–86.
   PubMed Web of Science ®Google Scholar
• Wan L, Sun M, Liu GJ, et al. Long noncoding RNA PVT1 promotes non-small cell lung cancer cell proliferation through epigenetically regulating LATS2 expression. Mol Cancer Ther. 2016;15:1082–1094.
   PubMed Web of Science ®Google Scholar
• Calses PC, Crawford JJ, Lill JR, et al. Hippo pathway in cancer: aberrant regulation and therapeutic opportunities. Trends Cancer. 2019;5:297–307.
   PubMed Web of Science ®Google Scholar
• Aylon Y, Michael D, Shmueli A, et al. A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev. 2006;20:2687–2700.
   PubMed Web of Science ®Google Scholar
• Chen R, Liu Y, Zhuang H, et al. Quantitative proteomics reveals that long non-coding RNA MALAT1 interacts with DBC1 to regulate p53 acetylation. Nucleic Acids Res. 2017;45:9947–9959.
   PubMed Web of Science ®Google Scholar
• Mahmoudi S, Henriksson S, Corcoran M, et al. Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell. 2009;33:462–471.
   PubMed Web of Science ®Google Scholar
• Li XL, Subramanian M, Jones MF, et al. Long noncoding RNA PURPL suppresses basal p53 levels and promotes tumorigenicity in colorectal cancer. Cell Rep. 2017;20:2408–2423.
   PubMed Web of Science ®Google Scholar
• Chaudhary R, Gryder B, Woods WS, et al. Prosurvival long noncoding RNA PINCR regulates a subset of p53 targets in human colorectal cancer cells by binding to matrin 3. Elife. 2017;6:pii:e23244.
   PubMed Web of Science ®Google Scholar
• Schmitt AM, Garcia JT, Hung T, et al. An inducible long noncoding RNA amplifies DNA damage signaling. Nat Genet. 2016;48:1370–1376.
   PubMed Web of Science ®Google Scholar
• Hu WL, Jin L, Xu A, et al. GUARDIN is a p53-responsive long non-coding RNA that is essential for genomic stability. Nat Cell Biol. 2018;20:492–502.
   PubMed Web of Science ®Google Scholar
• Hung T, Wang Y, Lin MF, et al. Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet. 2011;43:621–629.
   PubMed Web of Science ®Google Scholar
• Zhang HY, Yang W, Zheng FS, et al. Long non-coding RNA SNHG1 regulates zinc finger E-box binding homeobox 1 expression by interacting with TAp63 and promotes cell metastasis and invasion in Lung squamous cell carcinoma. Biomed Pharmacother. 2017;90:650–658.
   PubMed Web of Science ®Google Scholar
• Tanis SEJ, Koksal ES, van Buggenum J, et al. BLNCR is a long non-coding RNA adjacent to integrin beta-1 that is rapidly lost during epidermal progenitor cell differentiation. Sci Rep. 2019;9:31.
   PubMed Web of Science ®Google Scholar
• Lu X, Yu Y, Tan S. Long non-coding XIAP-AS1 regulates cell proliferation, invasion and cell cycle in colon cancer. Artif Cells Nanomed Biotechnol. 2019;47:767–775.
   PubMed Web of Science ®Google Scholar
• Sanger HL, Klotz G, Riesner D, et al. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci U S A. 1976;73:3852–3856.
   PubMed Web of Science ®Google Scholar
• Nigro JM, Cho KR, Fearon ER, et al. Scrambled exons. Cell. 1991;64:607–613.
   PubMed Web of Science ®Google Scholar
• Jeck WR, Sorrentino JA, Wang K, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013;19:141–157.
   PubMed Web of Science ®Google Scholar
• Salzman J, Gawad C, Wang PL, et al. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS One. 2012;7:e30733.
   PubMed Web of Science ®Google Scholar
• Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495:333–338.
   PubMed Web of Science ®Google Scholar
• Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495:384–388.
   PubMed Web of Science ®Google Scholar
• Yang Q, Du WW, Wu N, et al. A circular RNA promotes tumorigenesis by inducing c-myc nuclear translocation. Cell Death Differ. 2017;24:1609–1620.
   PubMed Web of Science ®Google Scholar
• Li Z, Huang C, Bao C, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015;22:256–264.
   PubMed Web of Science ®Google Scholar
• Du WW, Yang W, Liu E, et al. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. Nucleic Acids Res. 2016;44:2846–2858.
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhao K, Xu X, et al. A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma. Nat Commun. 2018;9:4475.
   PubMed Web of Science ®Google Scholar
• Holdt LM, Stahringer A, Sass K, et al. Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. Nat Commun. 2016;7:12429.
   PubMed Web of Science ®Google Scholar
• Cai H, Zhang P, Xu M, et al. Circular RNA hsa_circ_0000263 participates in cervical cancer development by regulating target gene of miR-150-5p. J Cell Physiol. 2019;234:11391–11400.
   PubMed Web of Science ®Google Scholar
• Su W, Sun S, Wang F, et al. Circular RNA hsa_circ_0055538 regulates the malignant biological behavior of oral squamous cell carcinoma through the p53/Bcl-2/caspase signaling pathway. J Transl Med. 2019;17:76.
   PubMed Web of Science ®Google Scholar
• Yang Z, Qu CB, Zhang Y, et al. Dysregulation of p53-RBM25-mediated circAMOTL1L biogenesis contributes to prostate cancer progression through the circAMOTL1L-miR-193a-5p-Pcdha pathway. Oncogene. 2019;38:2516–2532.
   PubMed Web of Science ®Google Scholar
• Amodio N, Stamato MA, Juli G, et al. Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia. 2018;32:1948–1957.
   PubMed Web of Science ®Google Scholar
• Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368:1685–1694.
   PubMed Web of Science ®Google Scholar
• Mahmoodi Chalbatani G, Dana H, Gharagouzloo E, et al. Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach. Int J Nanomedicine. 2019;14:3111–3128.
   PubMed Web of Science ®Google Scholar
• Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438:685–689.
   PubMed Web of Science ®Google Scholar
• Huang Y. Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics. Mol Ther Nucleic Acids. 2017;6:116–132.
   PubMedGoogle Scholar
• Wang WT, Han C, Sun YM, et al. Noncoding RNAs in cancer therapy resistance and targeted drug development. J Hematol Oncol. 2019;12:55.
   PubMed Web of Science ®Google Scholar
• Matsui M, Corey DR. Non-coding RNAs as drug targets. Nat Rev Drug Discov. 2017;16:167–179.
   PubMed Web of Science ®Google Scholar